Numerous studies demonstrated the feasibility and effectiveness of HSP70 vaccines in combination with other substances, such as tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), or proved the efficacy of tumor vaccines, as dendritic cell (DC), DNA, protein, or tumor cell lysate vaccines in anti-cancer therapies (Table 2). The gene discussed is HSPA1A; the disease is neoplasm.